Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors.

× No keyword cloud information.

24 in total

1. Gene therapy for immunological tolerance: using 'transgenic' B cells to treat inhibitor formation.

Authors: D W Scott
Journal: Haemophilia Date: 2010-05 Impact factor: 4.287

2. Modulation of factor VIII-specific memory B cells.

Authors: B M Reipert; P Allacher; C Hausl; A G Pordes; R U Ahmad; I Lang; J Ilas; J Windyga; A Klukowska; E M Muchitsch; H P Schwarz
Journal: Haemophilia Date: 2010-05 Impact factor: 4.287

Review 3. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors: Carol H Miao
Journal: Expert Rev Hematol Date: 2010-08 Impact factor: 2.929

Review 4. Strategies towards a longer acting factor VIII.

Authors: E L Saenko; S W Pipe
Journal: Haemophilia Date: 2006-07 Impact factor: 4.287

5. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

Authors: Chao-Lien Liu; Peiqing Ye; Benjamin C Yen; Carol H Miao
Journal: Mol Ther Date: 2011-04-05 Impact factor: 11.454

6. Induction of tolerance to factor VIII by transient co-administration with rapamycin.

Authors: B Moghimi; B K Sack; S Nayak; D M Markusic; C S Mah; R W Herzog
Journal: J Thromb Haemost Date: 2011-08 Impact factor: 5.824

7. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

Authors: Braden Waters; Mohammad Qadura; Erin Burnett; Rouzbeh Chegeni; Andrea Labelle; Patrick Thompson; Christine Hough; David Lillicrap
Journal: Blood Date: 2008-09-24 Impact factor: 22.113

8. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

Authors: Baowei Peng; Peiqing Ye; David J Rawlings; Hans D Ochs; Carol H Miao
Journal: Blood Date: 2009-09-21 Impact factor: 22.113

9. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.

Authors: Hideto Matsui; Masaru Shibata; Brian Brown; Andrea Labelle; Carol Hegadorn; Chandler Andrews; Marinee Chuah; Thierry VandenDriessche; Carol H Miao; Christine Hough; David Lillicrap
Journal: Blood Date: 2009-05-20 Impact factor: 22.113

Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors.

1. Gene therapy for immunological tolerance: using 'transgenic' B cells to treat inhibitor formation.

2. Modulation of factor VIII-specific memory B cells.

Review 3. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Review 4. Strategies towards a longer acting factor VIII.

5. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

6. Induction of tolerance to factor VIII by transient co-administration with rapamycin.

7. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

8. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

9. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.

Review 10. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII.

Review 1. Complexity of immune responses to AAV transgene products - Example of factor IX.

Review 2. Progress toward inducing immunologic tolerance to factor VIII.

Review 3. Gene Therapy With Regulatory T Cells: A Beneficial Alliance.